Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic

Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design. NEW YORK, August 4th, 2026 (GLOBE NEWSWIRE) — Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this agreement, the companies will advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2